News

Careful use of anti-vascular endothelial growth factor agents for the treatment of age-related macular degeneration is acceptable, but physicians should be alert for exceptions to the expected outcome.

Some practical advice and common-sense tips can help clinicians stay abreast of developments and possible malpractice cases.

Most eye-care practitioners are unlikely to read any journal cover to cover, and perhaps they may consider meibomian gland dysfunction underwhelming as a topic at a time when there are a number of exciting developments in vision research.

Results from a phase III study investigating intravitreal ranibizumab for the treatment of DME show that the anti-vascular endothelial growth factor agent was well-tolerated and met its primary efficacy endpoint.

The recently published report from the International Workshop on Meibomian Gland Dysfunction provides an evidence-based review of current knowledge about meibomian gland structure and function in health and disease, offers an idea bank for researchers with an interest in the field, and provides practical guidance to clinicians on the evaluation and management of a very common disorder.

After enduring several disappointing drug trials of treatments that once held promise for dry eye and cystic fibrosis, Inspire Pharmaceuticals will become part of Merck & Co. Inc. in a $430 million acquisition.

If you feel that you have flow issues in your office, stop being the technician's safety valve for poor behavior.

A new quinazolinone compound represents a novel approach to management of choroidal neovascularization.

Periocular injections of steroids improve active inflammation and macular edema in most patients with uveitis.

Sustained release fluocinolone acetonide has the potential to become an effective long-term treatment for DME.

Measure your inventory turns monthly.

The author discusses how MGD is a major source of morbidity and decreased quality of life for patients.

The pivotal study of a sustained-release dexamethasone intravitreal implant showed that it was a safe, effective option for the treatment of noninfectious intermediate and posterior uveitis.

In patients who have not undergone previous treatment, bevacizumab appears to be a safe and effective treatment for exudative age-related macular degeneration.

The key success factor for turning ideas into reality is planning.

Most aspects of ocular trauma are unique when practicing in a combat environment.

A single intravitreal injection of ocriplasmin is safe, effective, well-tolerated, and is the first pharmacologic treatment for symptomatic vitreomacular adhesion.

On March 16, LENSAR Inc. received 510 (k) clearance from the FDA to market its femtosecond laser system for lens fragmentation in addition to anterior capsulotomy during cataract surgery.

Given the unprecedented growth of interest in correction of monochromatic optical aberrations to improve the quality of pseudophakic vision, it is natural that the next step will be to investigate polychromatic light and its inherent aberrations.

What is in your lens toolbox?

A 3-D simultaneous stereoscopic retinal camera that allows stereo images to be taken in one shot, offers an automatic mosaic merge function, and provides a full 45-degree field angle in two-dimensional mode has been introduced by Kowa Optimed Inc.

The use of a trabecular microbypass stent in combination with cataract surgery in patients with mild-to-moderate open-angle glaucoma is safe and results in clinically safe and statistically significant reductions in IOP with fewer medications when compared with cataract surgery alone.

The debate over the need to remove the corneal epithelium when performing corneal collagen crosslinking will continue until long-term data from peer-reviewed studies become available to answer the question of whether a procedure done with the epithelium on results in sufficient crosslinking for long-term arrest of ectasia progression.

Potential treatments for the management of dry age-related macular degeneration are numerous, but so far, studies still are ongoing as to their therapeutic benefit.

A proprietary surgery system brings to laser vision correction surgeons the benefits of expertise in both femtosecond and excimer laser technology.

Oral fenretinide slowed the growth of geographic atrophy and reduced the incidence of choroidal neovascularization in patients who were treated over a 2-year period with a daily dose of the drug.

Ophthalmic medical device company Glaukos Corp. has been named to the Wall Street Journal?s ?The Next Big Thing? list, which ranks the 50 venture-backed companies it deems most promising.

Scotia Vision LLC and i2eye Consulting LLC are merging in a move designed to strengthen the former company?s business model. The combined entity will be known as Scotia Vision.

A generic version of latanoprost ophthalmic solution 0.005% is now available following the FDA's final approval of Mylan Pharmaceutical's abbreviated new drug application for a former proprietary solution (Xalatan, Pfizer) to lower IOP in patients with ocular hypertension or glaucoma.

Alcon is now a division of Novartis AG that is headquartered in Fort Worth, TX, following the April 8 completion of a merger agreement between the two companies.